Verily

Verily Life Sciences LLC, also known as Verily (formerly Google Life Sciences), is Alphabet Inc.'s research organization devoted to the study of life sciences. The organization was formerly a division of Google X, until August 10, 2015, when Sergey Brin announced that the organization would become an independent subsidiary of Alphabet Inc. with restructuring completed on October 2, 2015. On December 7, 2015, Google Life Sciences was renamed Verily.

Early Researchers
At the time of Verily's formation in 2015, the members of the research team that contributed to the founding patent portfolio include:

• Andrew Conrad

• Brian Otis

• Eric Teller

• Will Biederman

• Anupam Pathak

• Babak Amirparviz

• Nathan Pletcher

• Harvey Ho

• Zenghe Liu

• James Etzkorn

• Ehsan Saeedi

• Olivia Hatalsky

• Jeffrey George Linhardt

• Stephen O’Driscoll

• Eric Peeters

• Daniel Barrows

• Daniel Yeager

• Huanfen Yao

• Andrew Nelson

• Robert Francis Wiser

• Frank Honore

• Alice Lin

• Jason Thompson

• Vikram Singh Bajaj

• Mark Askew

• Douglas Weibel

• Sarel Kobus Jooste

• Alireza Dastgheib

• Victor Marcel Acosta

• Andrew Homyk

• Hao Du

• Xiaoyu Miao

• Peter H. Smith

• Christopher Jones

• John Lapetina

• Russell Norman Mirov

• Tamara Lynn Troy

• Brian Taewon Park

• David Andrew Gibson

• Mark Murphy

• Patrick Lin Wheeler

• Ramesh C. Bhardwaj

• Travis Deyle

• Scott B. Kennedy

• Shungneng Lee

• Jennifer Han

• Xiaoyu Miao

• Joshua Logan Howard Brimdyr

History
On 9 September 2014, the division acquired Lift Labs, the makers of Liftware.

Verily Life Sciences in January 2019 raised $1 billion in funding.

At the end of 2019, Verily sold its stake in robot-assisted surgery joint venture Verb Surgical to development partner Johnson & Johnson.

In August 2020, Verily announced that it is entering into the insurance market with the launch of Coefficient Insurance Company. The new subsidiary will be backed by Swiss Re Group's commercial insurance unit.

In September 2022, Verily announced longtime CEO Andy Conrad would step down as CEO in January 2023, to be replaced by Stephen Gillett who became CEO on January 3, 2023.

In January 2023, fifteen percent of Verily's workforce was laid off as part of a broader restructuring by parent company, Alphabet. The Information reported in August that Gillett had told employees they would stop relying on Alphabet on "a wide range of corporate services", signaling a potential spin-out as an independent company.

In June 2024, Verily decided to close its operations in Israel three years after opening a research and development center in the country. Verily staff in Israel are expected to leave by the third quarter of 2024. The company cited an effort to refocus its strategy on core products and projects as the reason for the closure.

Projects

 * The Dexcom G7 continuous glucose monitors (CGM), developed in partnership with Dexcom, was FDA approved and launched worldwide in 2022.
 * Galvani Bioelectronics, treating chronic conditions, including Rheumatoid Arthritis (RA), through targeted neuromodulation therapies, a joint venture with GlaxoSmithKline
 * Verb Surgical, for advancements in surgical robotics, a joint venture with Johnson & Johnson.
 * A spoon for people with tremors as part of Lift Labs acquisition.
 * The Baseline Study, a project to collect genetic, molecular, and wearable device information from enough people to create a picture of what a healthy human should be.
 * Onduo, a chronic disease management platform for patient with Diabetes, developed in partnership with Sanofi.
 * Study Watch, a health-tracking watch for clinical trials.

Discontinued

 * Contact lenses that allow people with diabetes to continually check their glucose levels using a non-intrusive method. On November 16, 2018, Verily announced it discontinued this project.
 * Smart shoes for health tracking and fall detection
 * Skin research with L’Oréal
 * A disease-detecting nanoparticle platform working with the wristband, a project called Tricorder.